4.7 Article

Poly(I:C) enhances mesenchymal stem cell control of myeloid cells from COVID-19 patients

期刊

ISCIENCE
卷 25, 期 5, 页码 -

出版社

CELL PRESS
DOI: 10.1016/j.isci.2022.104188

关键词

-

资金

  1. Thistledown Foundation
  2. Emergent Ventures (Fast Grant)
  3. Ottawa Hospital Foundation COVID-19 Emergency Response Fund
  4. Ontario Institute of Regenerative Medicine-Disease Team Grant

向作者/读者索取更多资源

This study found that viral mimic-priming enhances the ability of mesenchymal stem cells (MSCs) to regulate immune responses in COVID-19, reducing inflammation and enhancing antiviral functions.
Mesenchymal stem cells (MSCs) are being studied for the treatment of COVID-19-associated critical illness, due to their immunomodulatory properties. Here, we hypothesized that viral mimic-priming improves MSCs' abilities to rebalance the dysregulated immune responses in COVID-19. Transcriptome analysis of poly(I:C)-primed MSCs (pIC-MSCs) showed upregulation of pathways in antiviral and immunomodulatory responses. Together with increased expression of antiviral proteins such as MX1, IFITM3, and OAS1, these changes translated to greater effector functions in regulating monocytes and granulocytes while further enhancing MSCs' ability to block SARS-CoV-2 pseudovirus entry into epithelial cells. Most importantly, the addition of pIC-MSCs to COVID-19 patient whole blood significantly reduced inflammatory neutrophils and increased M2 monocytes while enhancing their phagocytic effector function. We reveal for the first time that MSCs can be primed by Toll-like receptor 3 agonist to improve their ability to rebalance the dysregulated immune responses seen in severe SARS-CoV-2 infection.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据